News | November 12, 2021
Solara Active Pharma Sciences PAT slides to Rs 29.71 cr in Q2FY22
Solara Active Pharma Sciences has reported consolidated financial results for the period ended September 30, 2021.
Solara Active Pharma Sciences has reported consolidated financial results for the period ended September 30, 2021.
J. B. Chemicals & Pharmaceuticals Limited (JBCPL), announced its financial results for the second quarter ended 30th September, 2021
The consideration for the acquisition is US $ 2.25 million
LSDCheck is CE-IVD approved LCMSMS-based testing kit for LSD in newborns
It was recognized for its holistic initiatives designed to improve the quality of life and standards of care for patients
Positive results reinforce the improved efficacy seen with Opdivo-based treatments in four Phase 3 clinical trials in earlier-stage cancers, including lung cancer, bladder cancer, esophageal/gastroesophageal junction cancer and melanoma
A Sanofi R&D executive will join the Gyroscope Clinical Advisory Board to advise on matters related to the development of GT005 for geographic atrophy (GA).
The Lucent 3D Lumbar Interbody System features a functionally unique multi-component device manufactured in a 3D printing sequence
The company has operations in North America, Asia, and Europe,
In the overall study population through Day 28, no deaths were reported in patients who received Paxlovid as compared to 10 deaths in patients who received placebo
Subscribe To Our Newsletter & Stay Updated
